E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Delivery Systems of Anticancer Agents"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (31 July 2014)

Special Issue Editor

Guest Editor
Prof. Dr. Franco Dosio

Department of Science and Technology of Medicine, University of Torino, v. P. Giuria 9, I-10125 Torino, Italy
Website | E-Mail
Phone: +390116707082
Interests: anticancer drugs transport; use of protein carriers, polymers, lipids, etc

Special Issue Information

Dear Colleagues,

Developments in drug delivery approaches have led to significant improvements in drugs’ pharmacological efficacies. These developments have been particularly important for anticancer drugs, which are characterized by narrow therapeutic windows. These narrow windows are chiefly the result from the drugs’ high systemic toxicities.

The main objective of drug delivery system development is to promote the therapeutic effects of drugs. This is done by increasing a drug’s bioavailability, preventing side-effects, reducing degradation and loss of the drug, and (especially when the delivery system is targeted) reaching high concentrations in selected areas of the body. Equally important, developing more efficacious drug delivery methods may be cheaper than developing a new drug. Therefore, the development of efficient drug delivery systems remains an important challenge in medicine. Thus, several drug delivery and drug targeting systems are currently being developed for many classes of antitumoral agents.

An important class of anticancer agents is the antitubulins. Tubulins are able to alter mitosis; this leads to cellular death. Among this class, the taxanes (mainly paclitaxel and docetaxel) are widely employed in clinical treatments. Owing to their significant activity against a variety of tumors, taxanes have received considerable attention. Nevertheless, many different approaches have been developed to improve their safety profile and water solubility, in terms of both dosing schedules and delivery strategies. Nanoparticle-albumin bound paclitaxel represents an excellent example of the potency of innovative taxane-containing delivery systems. Indeed, several other approaches are also in development.

This Special Issue of Molecules, entitled “Delivery Systems of Anticancer Agents,” is dedicated to novel or optimized methods, materials, and approaches that are able to efficiently deliver taxanes moving from the bench to the clinic. Targeted delivery systems are also welcome. I encourage authors to submit research papers and comprehensive reviews for this Special Issue.

Prof. Dr. Franco Dosio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • liposomes, micelles, solid lipid nanoparticles, emulsions
  • micro and nanoparticles, nanoformulations
  • macromolecular conjugates and prodrugs
  • albumin nanoparticles
  • theranostic agents
  • modified oligonucleotides
  • polymer/dendrimer bioconjugates
  • nanotubes
  • polysaccharides conjugates
  • targeted delivery

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Cyclic Peptide-Capped Gold Nanoparticles for Enhanced siRNA Delivery
Molecules 2014, 19(9), 13319-13331; https://doi.org/10.3390/molecules190913319
Received: 9 June 2014 / Revised: 22 August 2014 / Accepted: 22 August 2014 / Published: 28 August 2014
Cited by 11 | PDF Full-text (1061 KB) | HTML Full-text | XML Full-text | Supplementary Files
Previously, we have reported the synthesis of a homochiral l-cyclic peptide [WR]5 and its use for delivery of anti-HIV drugs and biomolecules. A physical mixture of HAuCl4 and the peptide generated peptide-capped gold nanoparticles. Here, [WR]5 and [WR]5-AuNPs
[...] Read more.
Previously, we have reported the synthesis of a homochiral l-cyclic peptide [WR]5 and its use for delivery of anti-HIV drugs and biomolecules. A physical mixture of HAuCl4 and the peptide generated peptide-capped gold nanoparticles. Here, [WR]5 and [WR]5-AuNPs were tested for their efficiency to deliver a small interfering RNA molecule (siRNA) in human cervix adenocarcinoma (HeLa) cells. Flow cytometry investigation revealed that the intracellular uptake of a fluorescence-labeled non-targeting siRNA (200 nM) was enhanced in the presence of [WR]5 and [WR]5-AuNPs by 2- and 3.8-fold when compared with that of siRNA alone after 24 h incubation. Comparative toxicity results showed that [WR]5 and [WR]5-AuNPs were less toxic in cells compared to other available carrier systems, such as Lipofectamine. Full article
(This article belongs to the Special Issue Delivery Systems of Anticancer Agents)

Graphical abstract

Back to Top